Multi-omics is the simultaneous analysis of multiple biological data layers—your genome, gene expression, microbiome composition, and metabolic output—to construct a unified picture of your health. Unlike single-assay testing that examines one dimension in isolation, multi-omics reveals how these systems interact, informing targeted interventions that address root causes rather than surface symptoms. At Akira Signature Care, we layer Viome microbiome RNA sequencing, Opus23 SNP analysis, and Function Health's 160+ biomarker panel to design protocols that match your individual biology.
What is multi-omics and why does it matter?
Multi-omics integrates data from genomics (your inherited DNA sequence), transcriptomics (which genes are actively expressed), proteomics (proteins produced), metabolomics (small molecules from metabolism), and metagenomics (your microbiome's genetic content). A 2020 Cell paper demonstrated that combining these layers improved disease prediction accuracy by 40% over single-omics approaches. Traditional medicine typically examines one data type—say, a lipid panel or a single genetic test—which misses critical interactions. For example, two patients with identical MTHFR C677T variants may require entirely different methylation support depending on their microbiome's folate production capacity and current homocysteine levels. Multi-omics captures these nuances. The approach transforms static snapshots into dynamic maps, revealing not just what variants you carry but how they manifest in your current physiology.
How Viome microbiome RNA differs from legacy 16S testing
Viome uses whole-genome metatranscriptomic sequencing—measuring microbial RNA, not just DNA—to assess which genes your gut bacteria are actively expressing. Legacy 16S rRNA sequencing, by contrast, identifies bacterial species based on a single conserved gene, offering a census without functional insight. Research published in Nature Biotechnology showed that 16S testing often misses 30-40% of microbial diversity and provides no information about metabolic activity. Viome's approach quantifies production of short-chain fatty acids, lipopolysaccharide (a driver of systemic inflammation), and neurotransmitter precursors like GABA and serotonin. It also scores gut lining health by measuring protein expression linked to tight junction integrity. This matters clinically: a patient may have abundant Akkermansia muciniphila on 16S (often marketed as beneficial) yet Viome reveals those bacteria are actively producing inflammatory metabolites due to dietary mismatch. We use this functional data to guide prebiotic selection, polyphenol dosing, and macronutrient ratios, moving beyond generic probiotic recommendations.
How Opus23 SNP analysis informs methylation, detox, and hormone pathways
Opus23 analyzes approximately 775,000 single nucleotide polymorphisms (SNPs) from a raw data file (23andMe, AncestryDNA, or clinical genotyping) and maps them onto biochemical pathways. Unlike consumer genetic reports that flag isolated variants, Opus23 shows compound heterozygosity and pathway-level impact. Studies in Pharmacogenomics confirm that single-variant interpretation often misleads: MTHFR A1298C alone rarely impairs methylation, but combined with COMT V158M and low riboflavin intake, it can significantly reduce neurotransmitter clearance. Opus23 visualizes methylation cycles (folate → methionine → SAMe → homocysteine), detoxification phases (CYP450 enzymes, glutathione conjugation, COMT/SULT activity), estrogen metabolism (2-OH vs 4-OH vs 16-OH pathways), and histamine breakdown (DAO, HNMT variants). In our clinic, we overlay this genomic map with current biomarkers—serum homocysteine, methylmalonic acid, oxidized LDL, estrogen metabolites via DUTCH testing—to determine which variants are expressing clinically. For instance, a patient with slow COMT (Met/Met) and high urinary 4-hydroxyestrone needs different support than one with fast COMT (Val/Val) and low 2-OH estrogen, even if both have BRCA mutations.
How Function Health's 160+ biomarker panel completes the picture
Function Health measures over 160 biomarkers across metabolic, endocrine, cardiovascular, liver, kidney, immune, and nutritional categories, including advanced markers rarely ordered in standard care: ApoB, Lp(a), hs-CRP, insulin, HbA1c, thyroid antibodies, sex hormones, cortisol, DHEA-S, vitamin D, B12, folate, magnesium RBC, and heavy metals. Research in the Journal of Clinical Endocrinology & Metabolism found that insulin resistance is detectable via fasting insulin and HOMA-IR years before fasting glucose rises, yet these markers are seldom screened. Function's comprehensive panel reveals subclinical dysfunction—elevated liver enzymes suggesting NAFLD, low free T3 despite normal TSH, or ApoB elevation (a better cardiovascular predictor than LDL-C per Lancet meta-analysis) masked by acceptable total cholesterol. We use these biomarkers to validate genomic and microbiome predictions: if Opus23 flags poor glutathione recycling (GSTM1 null, slow GPX variants) and elevated oxidized LDL or high GGT confirms oxidative stress, we implement NAC, selenium, and glycine support with measurable targets. The quarterly retesting Function enables creates accountability and allows real-time protocol adjustment—precision medicine requires feedback loops, not one-time snapshots.
Integrating all three: a real clinical workflow
Consider a 48-year-old woman presenting with fatigue, brain fog, and weight gain despite clean eating. Function Health reveals fasting insulin 18 µIU/mL (goal <5), hs-CRP 4.2 mg/L, low free T3, and ferritin 12 ng/mL. Viome microbiome analysis shows reduced butyrate production, elevated proteobacteria, and low intestinal alkaline phosphatase—markers of compromised gut barrier and endotoxemia. Opus23 identifies MTHFR C677T (homozygous), slow COMT (Met/Met), PEMT rs12325817 (impairing choline synthesis), and FUT2 non-secretor status (linked to dysbiosis susceptibility per Gut Microbes research). The integration: insulin resistance is driven partly by LPS translocation (microbiome), worsened by impaired hepatic methylation (genomics), manifesting as low thyroid conversion and inflammation (biomarkers). Protocol: increase butyrate substrates (resistant starch, polyphenols), supplement methylated B vitamins dosed to homocysteine target, add phosphatidylcholine for PEMT support, optimize iron and selenium for thyroid, implement time-restricted eating. Retest in 12 weeks: insulin drops to 6, hs-CRP to 0.9, ferritin normalizes, symptoms resolve. This outcome is impossible without integrating all three data streams—each alone would miss critical leverage points.
Why this approach is the future of preventive medicine
The 2015 Precision Medicine Initiative projected that integrating genomic, environmental, and lifestyle data would enable prediction and prevention of disease at the individual level. Multi-omics operationalizes that vision. A 2021 Nature Medicine study tracking 1,253 participants with longitudinal multi-omics profiling detected actionable health risks (prediabetes, dyslipidemia, early cancer markers) in 67% of participants, most of whom were asymptomatic. The limitation of reactive healthcare is clear: by the time standard labs flag disease, years of subclinical dysfunction have passed. Multi-omics shifts the paradigm from diagnosis to early detection and optimization. At Akira Signature Care, we view this data not as an end but as a foundation—genomic context explains why certain imbalances occur, microbiome analysis shows what is happening now, and biomarkers measure how well interventions work. Together, they enable truly personalized care: protocols designed for your biology, monitored with precision, and adjusted in real time.
